Prescribing Quetiapine

At a glance

Effects shift with dose, but the label sets no tiers (300 mg bipolar depression, 150–750 mg schizophrenia). First-tier only for bipolar depression.

How to doseFull section

Comes as

IR tablet25, 50, 100, 200, 300, 400 mg (can be crushed)

XR tablet (Seroquel XR)50, 150, 200, 300, 400 mg

Example photos; looks vary by maker. Click to enlarge.

In shortPick the dose for the use: 300 mg a day for bipolar depression, 400–800 mg for mania, 150–750 mg for schizophrenia (IR). 25–50 mg is a sedative dose. The label titrates fast; outpatients usually start low and go up slowly.

FDA labelIn practice

A row across both columns means the label and usual practice agree. Off-label marks the few places where practice goes beyond what the label allows.

Adults, by use

Bipolar depressionFDA labelAt bedtime: 50 mg day 1, 100 mg day 2, 200 mg day 3, 300 mg day 4. Maximum 300 mg.In practiceStart 25 mg (50 mg if XR). Raise 50 mg every 4–7 days to 300 mg. 600 mg is no better.

Schizophrenia (IR)FDA label25 mg twice daily on day 1; 300–400 mg a day by day 4. Usual 150–750 mg. Maximum 750 mg.In practiceStart 25 mg (some protocols: 25 mg twice daily). Raise 50 mg every 3–4 days. Inpatients can use steps of 100 mg a day.

Schizophrenia (XR)FDA label300 mg on day 1; raise by up to 300 mg a day. Usual 400–800 mg. Maximum 800 mg.In practiceStart 50 mg. Raise 50 mg every 3–4 days.

Bipolar maniaFDA labelIR: 100 mg on day 1, 400 mg by day 4, up to 800 mg by day 6. Usual 400–800 mg. Maximum 800 mg.In practiceOutpatients: raise 50 mg every 3–4 days to 400–800 mg a day, often divided. Inpatients can use steps of 100 mg a day.

Depression add-on (XR)FDA label50 mg on days 1 and 2, 150 mg on day 3. Usual 150–300 mg. Maximum 300 mg.In practiceConsider 150 mg first for tolerability.

Bipolar maintenanceFDA labelAdd-on to lithium or divalproex: 400–800 mg a day, generally the dose the patient was stabilized on. IR: twice daily. Maximum 800 mg.

Sleep (off-label)FDA labelNo labeled doseIn practice25–50 mg at bedtime. Use it as a deliberate exception.

Ages 10–17FDA labelIR: same day-by-day titration to 400 mg a day by day 5. Usual 400–800 mg (schizophrenia) or 400–600 mg (mania).In practiceStart low, titrate slowly, and watch weight and metabolic labs closely.

Older adultsFDA labelStart 50 mg a day; increase in steps of 50 mg a day, by response.In practiceStart 25 mg and titrate weekly, not daily. Often effective at 100–200 mg at bedtime.

Liver impairmentFDA labelIR: start 25 mg a day, raise by 25–50 mg a day. XR: start 50 mg, raise by 50 mg.

With CYP3A4 drugsFDA labelStrong inhibitor (ketoconazole, ritonavir, nefazodone): one-sixth of the dose. Strong inducer (carbamazepine, phenytoin) over 7–14 days: up to 5-fold.In practiceInhibitors: watch for sedation. Inducers: avoid, or pick another antipsychotic.

When to take itFDA labelIR: with or without food. XR: in the evening, without food or with a light meal.In practiceIR: at bedtime for most uses; divided doses for schizophrenia and mania. XR: about 12 hours before waking.

StoppingFDA labelThe dosing section of the label gives no taper schedule.In practiceTaper over weeks, for example about 50 mg every 3–7 days. Watch for rebound insomnia and anxiety.

IndicationsFull section

FDA-approved

Schizophrenia, acute and maintenance (adults; 13–17)

Bipolar mania, acute, alone or adjunct (adults; 10–17)

Bipolar depression, monotherapy

Bipolar I maintenance, adjunct to lithium/divalproex

MDD, adjunct to an antidepressant (XR)

Off-label, evidence-based

Comorbid anxiety in bipolar disorderGAD, severe refractory (third/fourth line)PTSD, re-experiencing and hyperarousal (~258 mg)Insomnia, 25–50 mg (deliberate exception only)Borderline personality disorder (low dose)

Boxed warningsFull section

Dementia-related psychosis mortalityRisk ~1.6–1.7x; not approved for it: avoid, or lowest dose for the shortest time

Suicidality in youth and young adults (depression use)Antidepressant class warning; monitor closely, especially early in treatment

ContraindicationsFull section

No absolute contraindication named in this guide.

MonitorFull section

Weight/BMIBaseline, monthly × 3 mo, then every 3 mo; act at >1 lb/mo or ≥5–7%

Fasting glucose/A1cBaseline, ~12 wk, then annually (more often if gaining)

Fasting lipidsBaseline, 3 mo, then every 2 yr (annually if abnormal)

BP, orthostaticsBaseline supine and standing; each visit early in titration

Polyuria, polydipsia, sedationAsk every visit

Lens examAt start and every 6 mo with chronic use (label)

ECGOnly with cardiac risk or QT-prolonging co-meds

Prolactin only if symptomatic. Refer to PCP if LDL >130 mg/dL.

Drug interactionsFull section

Drug-drug

Carbamazepine (strong 3A4 inducers)Renders quetiapine all but inert; avoid, or pick a different antipsychotic

LamotrigineLevels ran 58% lower (probably glucuronidation); monitor response, not forbidden

Alcohol, opioids, benzodiazepinesAdditive sedation and respiratory depression; co-prescribe cautiously

Ketoconazole, clarithromycin, grapefruit3A4 inhibitors (erythromycin too) raise levels; watch for excess sedation

Other QT-prolonging drugsAdditive QT risk; use judgment in cardiac patients

Other anticholinergicsAdditive dry mouth, constipation, retention, confusion, esp. in the elderly

CYP enzymes

CYP3A4Primary substrateInhibitors raise levels; strong inducers (carbamazepine) collapse them

Itself not a major CYP inducer or inhibitor.

Must counselFull section

SleepinessStrong at first, usually much better in 1–2 weeks; take it at bedtime

Weight gainCommon over months; we weigh you monthly and act early

Dizziness on standingSit on the bed edge first, then stand slowly; sit down if dizzy

Constipation, dry mouthUse the stool softener nightly; water and sugar-free gum

Thirst, urinating moreCan signal high blood sugar; tell me

Alcohol, sedativesAvoid stacking alcohol, opioids or sleeping pills

StoppingDo not stop suddenly: rebound insomnia and nausea; we taper

PearlsFull section

Ask which quetiapine you want. At 25–50 mg for sleep you get a sedative plus metabolic and TD risk (~2.5%/yr); a cleaner sleep drug usually wins.

Bipolar depression is its home: 300 mg qHS, NNT ~6, and it works in bipolar II too. 600 mg adds only side effects.

Bipolar depression: pushing past 300 mg chases benefit that is not there and adds only side effects. Titrate to the target for the indication.

Lowest EPS and akathisia of the first-line atypicals: the choice in Parkinson's disease, after TBI or with an akathisia history.

Carbamazepine collapses levels; lamotrigine lowered them 58% in one database. Pick another antipsychotic rather than chasing the dose.

Summary of this guide. Check the full sections before prescribing.

Photo credits

Seroquel (quetiapine) 25 mg and 100 mg tablets: Luke-2, CC BY-SA 2.5, Wikimedia Commons

Seroquel 25 mg tablets beside a US cent for scale: Elbreapoly, Public domain, Wikimedia Commons

Quetiapine fumarate 50 mg tablets: INeverCry, CC0, Wikimedia Commons

Seroquel XR 150 mg, box: Fuse809, CC BY-SA 3.0, Wikimedia Commons

Why Quetiapine Matters, and Why It's So Often Misused

Quetiapine is one of the most prescribed psychiatric medications in the world and one of the most misunderstood. Clinicians reach for it constantly (for bipolar depression, sleep, anxiety, agitation, and augmentation of a stalled antidepressant), yet most prescribers never absorb how much the dose changes what the drug is doing.

The label defines no dose tiers. It lists 150–750 mg/day for schizophrenia and 300 mg/day for bipolar depression, and it attributes efficacy to combined D2 and 5-HT2 antagonism. What the label does give is receptor affinity: quetiapine binds histamine H1 receptors far more tightly than D2 receptors (Ki 4.4 nM against 626 nM), so H1 effects should appear at lower exposures than D2 blockade. That is the pharmacologic basis for using 25–50 mg for sedation, and it fits the label's own trial data: 450 mg/day beat 50 mg/day on the BPRS psychosis cluster. The common shorthand of 25–50 mg as an antihistamine, 150–300 mg as an antidepressant and 300 mg and above as an antipsychotic is a rule of thumb that the label does not state. It leaves 51–149 mg undefined, and in the label's fixed-dose schizophrenia trial 150 mg/day was already generally superior to placebo.

Quetiapine is a first-tier drug in one place, bipolar depression. It also works for a long list of secondary uses, but in those its side-effect burden (sedation and metabolic harm) should push it to third or fourth line. Prescribe it deliberately, match the dose to the mechanism you want, monitor the metabolic parameters religiously, and it is a useful drug. Prescribe it reflexively as a sleep aid or a PRN sedative and you accumulate weight gain, dyslipidemia, diabetes risk, and a small but real tardive dyskinesia liability for a benefit an antihistamine would have delivered for free.

Part 1: Indications

FDA-Approved Uses

• Schizophrenia (acute and maintenance)
• Bipolar mania (acute, monotherapy or adjunctive)
• Bipolar depression (monotherapy)
• Bipolar I maintenance (adjunctive to lithium or divalproex)
• Adjunctive treatment of major depressive disorder (Seroquel XR, approved 2009)

Quetiapine is not approved as monotherapy for unipolar depression, only as an add-on to a failed antidepressant.

Bipolar Depression: Its Best Indication

Bipolar depression is the indication that justifies the drug. It is hard to treat: antidepressant monotherapy is ineffective and can destabilize mood, and quetiapine has some of the best controlled evidence available.

• In the BOLDER I and II trials, quetiapine 300 mg QHS produced response rates of 52–58% versus 36–37% on placebo, with remission rates around 32% vs 20%.
• The number needed to treat is about 6, among the best figures for any bipolar depression treatment. Cariprazine's is about 10, but its trials used a stricter remission threshold, so the two figures do not compare directly.
• 600 mg offers no advantage over 300 mg; it only adds side effects. Few dosing facts in this guide matter more.
• Quetiapine has demonstrated efficacy in both the manic and depressive poles, and it works in bipolar II depression as well as bipolar I, which several competitors (cariprazine among them) have not shown.
• No treatment-emergent mania was seen over the 8-week trials.

Bipolar Maintenance and the Lithium Combination

Quetiapine is FDA-approved as adjunctive maintenance therapy with lithium or divalproex. Added to lithium, quetiapine lowered recurrence odds roughly 4-fold compared with lithium alone in maintenance (Nestsiarovich 2022). It also worked in bipolar II maintenance, where cariprazine did not.

Real-world data are less flattering. In the large Finnish nationwide cohort (Lähteenvuo 2018), quetiapine was the most frequently used antipsychotic in bipolar disorder but only modestly effective at preventing rehospitalization, outperformed by lithium and by long-acting injectables. Quetiapine is a reasonable maintenance agent, especially in combination, but not the strongest one available.

Schizophrenia: Approved, But Rarely the Best Choice

Quetiapine is FDA-approved for schizophrenia, but its effect size (~0.4) is medium and clearly below clozapine (0.9), olanzapine (0.55), and risperidone (0.55). In CATIE, 82% of the patients assigned to quetiapine stopped it during phase 1, the highest rate of the five drugs, at a mean modal dose of 543 mg/day within a protocol range of 200 to 800 mg.

Reserve quetiapine monotherapy for schizophrenia for the patient in whom EPS avoidance is paramount (see below). It is not a first-line choice for first-episode psychosis; aripiprazole, risperidone, and ziprasidone are preferred.

Secondary Uses

In these indications quetiapine works, but its side-effect burden should make it a later-line option:

• Unipolar depression augmentation (150–300 mg): modestly helpful, response ~58% vs 46% placebo, NNT ~7 at 300 mg. But the placebo accounts for 73–82% of the improvement, and 300 mg carries an 82% increase in dropout. Third or fourth line.
• Generalized anxiety disorder: paradoxically, quetiapine had the largest effect on the Hamilton Anxiety scale in a Lancet meta-analysis, beating escitalopram, duloxetine, and benzodiazepines, yet the FDA did not approve it for GAD. Its advisory committee voted unanimously that the drug was unsafe as first-line therapy in GAD or unipolar depression, citing sedation, tardive dyskinesia and metabolic harm. Third/fourth line for severe, refractory cases only.
• Comorbid anxiety in bipolar disorder: a real niche. Reduced anxiety in 20 of 27 placebo-controlled trials.
• PTSD: improved re-experiencing and hyperarousal (avg ~258 mg), and improved comorbid depression, but did not improve avoidance, negative symptoms, or, surprisingly, sleep. A reasonable option for psychotherapy non-responders.
• Insomnia (25–50 mg): improves sleep architecture and efficiency but not sleep latency. See the warning below.
• Borderline personality disorder (low dose): some anti-impulsivity/anxiolytic benefit.
• Delirium: two placebo-controlled trials were negative. Don't reach for it here.
• Dementia-related agitation and Parkinson's psychosis: weak evidence, and it falls under the boxed mortality warning. Avoid or use only briefly at the lowest dose.

Part 2: Mechanism

Quetiapine's receptor effects change with dose, but the label defines no dose tiers; the three ranges below are common shorthand that the label does not state.

Low Dose (25–50 mg): Sedation

• H1 antagonism is the strongest-binding action in the label's affinity table (Ki 4.4 nM) and produces sedation, the effect sought at this dose
• Alpha-1 antagonism causes orthostatic hypotension and dizziness
• M1 (muscarinic) antagonism causes dry mouth, constipation, and urinary hesitancy

Intermediate Dose (150–300 mg): Antidepressant Dosing

Serotonergic and noradrenergic activity emerges (partly via the active metabolite norquetiapine, a norepinephrine reuptake inhibitor and partial 5-HT1A agonist). This is the dose range used for bipolar depression (label: 300 mg/day) and for depression augmentation.

Higher Dose (300 mg and above): Antipsychotic Dosing

D2 antagonism contributes more as exposure rises. The label's schizophrenia range is 150–750 mg/day, and in one label trial the high-dose group that beat placebo averaged 500 mg/day.

Quetiapine is, like clozapine, a "light" dopamine blocker: heavy on 5-HT2A antagonism, comparatively light on D2. That profile is why it produces so little EPS and virtually no clinically meaningful prolactin elevation, and why it is the antipsychotic of choice when movement side effects must be avoided (Parkinson's disease, akathisia-prone young men, TBI patients).

Pharmacokinetics

• Metabolized primarily by CYP3A4; the drug itself is neither a major inducer nor inhibitor, so it is clean with most co-medications.
• IR half-life is short (~6–7 hours), so it is dosed QHS: the sedation helps at night, and the short half-life clears it by morning.
• Extensively metabolized by the liver: less than 1% of a dose is excreted unchanged, and about 73% is recovered in urine and 20% in feces as metabolites. Hepatic impairment lowers oral clearance about 30%, so the starting dose drops there.

Part 3: Before You Start: Workup and Candidacy

Quetiapine's risks are metabolic, not renal or hematologic, so the baseline workup targets exactly that.

Who Is a Poor Candidate?

• Metabolically vulnerable patients (obesity, diabetes, prediabetes, high triglycerides): prefer a metabolically cleaner agent (aripiprazole, lurasidone, ziprasidone)
• Fall-risk patients (elderly, mobility-impaired): orthostasis is a real hazard
• Patients with dementia-related psychosis: boxed warning, increased mortality; avoid
• Patients with daytime functional demands who cannot tolerate sedation (drivers, machine operators)
• Baseline QTc >500 ms or a history of serious arrhythmia

The historical QTc/torsades fear is overstated; real-world arrhythmia risk is much lower than once believed, and an ECG is not a routine prerequisite in a cardiovascularly healthy patient.

Part 4: How to Start and Dose

Formulations

• Immediate-release (IR): the default formulation. Dosed once at bedtime for bipolar depression, as the label directs, and often at bedtime for other uses in practice (sedation is desirable at night and the short half-life clears by morning); the label doses schizophrenia, mania and bipolar I maintenance twice daily. Can be crushed and mixed into food.
• Extended-release (Seroquel XR): once-daily; available 50, 150, 200, 300, 400 mg. Counsel on two points that matter: take it without food or with a light meal of about 300 calories, since a high-fat meal raises Cmax 44% to 52% and AUC 20% to 22% while a light meal does not; and take it ~12 hours before the desired wake time to minimize morning grogginess, since XR tends to cause more morning fatigue than IR.

Why Slow Titration Matters

Slow escalation blunts the early sedation, orthostasis, and dry mouth that otherwise drive patients off the drug. The early sedation is time-limited and usually improves dramatically within 1–2 weeks. Tell patients this up front. It is the single most useful piece of counseling for adherence.

Dose Adjustments and Special Populations

• QTc: quetiapine prolongs QTc modestly, so use caution with other QT-prolonging drugs, hypokalemia, and cardiac disease.
• Geriatric: clearance is ~30–50% lower, so titrate slowly; the class boxed warning applies.

Stopping and Switching

• Discontinuation: taper, because abrupt cessation can cause insomnia, nausea, and rebound. The short half-life makes discontinuation symptoms notable at higher doses.

Part 5: Monitoring

Quetiapine belongs to the "metabolically dirty" group of antipsychotics (with olanzapine, clozapine, risperidone), so monitoring centers on weight, glucose, and lipids.

Screening clinical questions each visit: ask about polyuria and polydipsia (screens for emerging diabetes) and about daytime sedation (drives non-adherence).

Action Thresholds

• Weight gain >1 lb/month in the first 3 months, or ≥5–7% of baseline weight: intervene, lifestyle counseling first, then consider metformin, then consider switching.
• Fasting glucose 100–125 (prediabetes) or ≥126 (diabetes): lifestyle, consider metformin, involve PCP.
• LDL >130 mg/dL: refer to PCP for lipid management.

Part 6: Side Effects and How to Manage Them

Quetiapine's problems are sedation early and metabolic harm late. The early sedation is time-limited and manageable with counseling; the metabolic harm is cumulative and demands active monitoring and intervention.

Sedation and Somnolence

Sedation is the characteristic side effect. In depression trials, ~37–39% at 150–300 mg reported sedation vs 5% on placebo. It is prominent in the first 1–2 weeks and then usually falls off dramatically.

• Dose QHS: turn the liability into a sleep aid.
• Titrate slowly (50 mg q3–4 days).
• Counsel that it is time-limited: this alone prevents many early discontinuations.
• If persistent daytime grogginess on XR, the IR formulation or earlier evening dosing may help.
• Avoid stacking other CNS depressants (alcohol, opioids, benzodiazepines, sedating antihistamines).

Metabolic: Weight, Glucose, Lipids

• Weight: ~2.6 lbs average in short (<2 month) trials, modest on paper, but short trials badly understate the truth. Long-term, 1 in 5 patients gains >7% of body weight after ≥9 months. Among atypicals it sits in the worse tier (better than olanzapine's ~6.4 lbs short-term, far worse than lurasidone 0.5 or aripiprazole 0.4).
• Glucose: clinically elevated in 6–7% at 300 mg XR (vs 1–3% placebo).
• Lipids: triglycerides rise predictably, usually tracking weight.

Management:

• Lifestyle counseling from day one (diet, exercise), not as an afterthought.
• Metformin is the best-evidenced pharmacologic option and is preferred over topiramate. A practical ramp: metformin XR 500 mg daily after the largest meal, then after 1 week 500 mg BID, titrate to 750 mg BID, up to 1,000 mg BID as tolerated. Start it early (within ~4–8 weeks) if weight gain appears; started concurrently it yields roughly 3–4 kg of benefit. Check a comprehensive metabolic panel and B12 annually on metformin.
• Switch agents if metabolic markers worsen meaningfully and the patient can tolerate a cleaner drug (aripiprazole, lurasidone, ziprasidone).

Anticholinergic Effects (Dry Mouth, Constipation, Urinary Hesitancy)

Driven by norquetiapine, the active metabolite, which has moderate to strong affinity for several muscarinic receptor subtypes. They show up at ordinary therapeutic doses.

• Dry mouth: water, sugar-free gum.
• Constipation: a prophylactic bowel regimen, as you would with opioids: docusate 100 mg QHS plus senna 17.2 mg QHS at initiation. Escalate to BID dosing if 48 hours pass without a bowel movement; add polyethylene glycol 17 g BID and examine if 4 days pass. Quetiapine (with olanzapine) carries more ileus risk than other atypicals though half that of clozapine; take constipation seriously, especially in the elderly or on other anticholinergics.
• Urinary hesitancy: monitor; caution in BPH.
• Cognitive dulling: the anticholinergic burden at therapeutic doses is real and can impair cognition; keep it in mind in older patients and those on other anticholinergics.

Orthostatic Hypotension

Quetiapine has meaningful alpha-1 blockade and can cause symptomatic orthostasis, especially early and in the elderly, and it is a real fall and fracture risk.

Measurement: sit ≥5 min, stand, wait 2 min, remeasure; a systolic drop ≥20 mmHg defines it (10–20 mmHg can still be symptomatic).

• Slow titration is the primary prevention.
• Behavioral: stay hydrated; rise slowly, hang legs over the bed edge, wait, then stand with support; sit down immediately if dizzy.
• Mechanical: an abdominal binder (6–8 inches wide) is more effective than compression stockings; apply it before getting out of bed (the highest-risk moment).

Movement Effects: Reassuringly Rare

Quetiapine has the lowest EPS and akathisia among first-line atypicals, a major reason to choose it. EPS was not elevated over placebo in depression trials.

Tardive dyskinesia risk is lower than with typical antipsychotics but not zero: annualized incidence runs about 2.6% for second-generation antipsychotics against 6.5% for first-generation ones in head-to-head trials (Carbon 2018), and about 2.5% for quetiapine in the same analysis (a non-randomized pooled estimate with a wide interval). An earlier pooled analysis (Correll and Schenk 2008) found 3.9% against 5.5%. Disclose it when planning long-term use, and reconsider the drug (especially at low "sleep" doses) if the benefit is marginal.

Cardiovascular

• QTc: the historical torsades fear is overstated; real-world arrhythmia risk is low. Avoid in baseline QTc >500 ms or arrhythmia history, and be cautious when stacking other QT-prolonging drugs.
• Tachycardia: reported, generally mild.

Other

• Cataracts: cataracts/lens changes seen in chronic dog studies and also observed in humans during long-term treatment, though a causal relationship is unproven; the FDA label recommends a lens (slit-lamp) exam at initiation and every 6 months during chronic use, so periodic ophthalmologic monitoring is advised for long-term patients.
• Hypothyroidism: dose-related decreases in thyroid hormone levels are a named label finding; usually subclinical and not routinely screened for, but worth a TSH if the patient develops fatigue or other hypothyroid symptoms.
• Seizures: rare, dose-related in animals; use cautiously in seizure disorders.

Part 7: Overdose, Toxicity, and Boxed Warnings

Overdose

Boxed Warnings

Quetiapine carries the two boxed warnings standard to the antipsychotic and antidepressant classes it straddles:

Neuroleptic Malignant Syndrome (NMS)

Rare but life-threatening: fever, rigidity, altered mental status, autonomic instability. Discontinue immediately, provide supportive care and cooling; consider dantrolene or bromocriptine if severe.

Part 8: Drug Interactions

Quetiapine is metabolized by CYP3A4 and is otherwise pharmacokinetically clean, with no major CYP inhibition or induction of its own. The interactions that matter:

The Two You Must Know

• Carbamazepine (and other strong 3A4 inducers): carbamazepine can render quetiapine all but inert, because it induces metabolism so powerfully that quetiapine levels collapse. Avoid the combination or expect it to fail. If a strong inducer is already on board, pick a different antipsychotic rather than chasing quetiapine to ever-higher doses.
• Lamotrigine: lowers quetiapine levels, probably by inducing its glucuronidation. In a Swedish therapeutic drug monitoring database, dose-corrected quetiapine concentrations ran 58% lower in patients also taking lamotrigine. Monitor whether quetiapine is still working. The combination needs watching, but it is not forbidden.

Additive Pharmacodynamic Interactions

• CNS depressants (alcohol, opioids, benzodiazepines, sedating antidepressants): additive sedation and respiratory depression, counsel and co-prescribe cautiously.
• Other QT-prolonging drugs: additive risk, use judgment in cardiac patients.
• Other anticholinergics: additive dry mouth, constipation, urinary retention, and confusion, particularly in the elderly.
• 3A4 inhibitors (ketoconazole, clarithromycin, erythromycin, grapefruit): raise quetiapine levels, watch for excess sedation.

The XR Formulation and Food

Not a drug interaction as such, but worth counseling: a high-fat meal raises the Cmax of Seroquel XR by 44% to 52%. Take it without food or with a light meal of about 300 calories.

Part 9: Special Populations

Pregnancy

Data are limited but generally reassuring relative to older agents. Quetiapine is used off-label for bipolar maintenance in pregnancy when maternal stability requires it. The dominant consideration is often not teratogenicity but maternal weight gain and metabolic effects, which raise gestational diabetes and birth-weight concerns. Weigh against the substantial risk of destabilized bipolar illness in pregnancy. Manage with a multidisciplinary team (OB, psychiatry, patient) and document a risk-benefit discussion.

Lactation

Quetiapine is excreted into breast milk in small amounts and is generally considered among the more compatible atypicals with breastfeeding. Monitor the infant for sedation and poor feeding. Coordinate with pediatrics.

Elderly

• Increased sensitivity: start 25 mg, titrate slowly (weekly, not daily); effective doses are often 100–200 mg QHS.
• Orthostatic hypotension is the dominant hazard: assess fall and fracture risk, measure orthostatics routinely, consider an abdominal binder.
• Anticholinergic burden can precipitate delirium and urinary retention.
• Dementia-related psychosis: avoid (boxed mortality warning). If antipsychotic use is unavoidable for severe agitation, quetiapine is often the least-bad choice (lowest EPS) at the lowest possible dose for the shortest time, but the CATIE-AD data showed significant adverse effects for a relatively modest benefit.
• On the plus side, in Parkinson's disease and after TBI, quetiapine is frequently the preferred antipsychotic because of its low EPS liability.

Pediatric

FDA-approved for schizophrenia in adolescents (ages 13-17) and for acute bipolar I mania in children and adolescents (ages 10-17, monotherapy); used off-label for aggression. Metabolic monitoring is even more critical in youth, since they are more vulnerable to weight gain. Start low, titrate slowly.

Renal Impairment

Minimal renal clearance; dose adjustment not routinely required. Monitor for accumulation only in severe failure (CrCl <10 mL/min).

Hepatic Impairment

Quetiapine is extensively metabolized by the liver, and hepatically impaired patients have about 30% lower mean oral clearance; in two of the eight patients studied, AUC and Cmax ran three times the usual. Start at 25 mg/day, increase in increments of 25–50 mg/day, and monitor closely.

Part 10: Discontinuation

Abrupt cessation can produce acute withdrawal symptoms, among them insomnia, nausea and vomiting. Across short-term XR monotherapy trials with a discontinuation phase, 12.1% of patients reported one or more discontinuation symptoms against 6.7% on placebo, and they usually resolved within a week. Two further things can happen when it is stopped abruptly. The first is rebound insomnia and anxiety, since the sedating, anxiolytic effects vanish suddenly; patients (especially those on it for sleep) often feel markedly worse for days to weeks, and this is a major reason low-dose quetiapine becomes hard to stop. The second is symptom relapse of the underlying psychosis, mania, or bipolar depression.

How to Stop

• Taper gradually, especially after prolonged use: a common approach is to reduce by ~50 mg every 3–7 days, or lower the dose every 1–2 weeks for long-term users.
• Watch for rebound insomnia, anxiety, and withdrawal-emergent dyskinesia (choreiform movements appearing 1–4 weeks after a too-rapid reduction; if it occurs, reinstate and taper more slowly).
• In bipolar maintenance: after ~6 months of stable recovery from a mood episode, quetiapine can often be tapered off if the patient remains on a mood stabilizer (lithium or valproate), with relapse risk comparable to continuing (Yatham 2016). Reinforce lifestyle anchors (regular sleep/wake times, exercise, Mediterranean diet), and know that about half of patients succeed on a second discontinuation attempt if the first fails.

Part 11: Quetiapine vs the Alternatives

A note on mortality: in the depression-augmentation literature, adding an antipsychotic to an antidepressant carried ~45% higher mortality than antidepressant augmentation alone, but within that class, quetiapine and aripiprazole had the lowest mortality risk, below olanzapine and risperidone. If you are going to augment with an antipsychotic, quetiapine is on the safer end.

Choosing an Atypical

Differentiate by side-effect profile:

• Need to avoid EPS (Parkinson's, young male, akathisia history) → quetiapine
• Need to avoid weight/diabetes → away from quetiapine, toward aripiprazole, lurasidone, ziprasidone
• Need sedation/anxiolysis/sleep as part of the therapeutic effect → quetiapine
• Need to avoid sedation (functional daytime demands) → away from quetiapine, toward aripiprazole, risperidone
• Bipolar depression, both poles, with anxiety/insomnia → quetiapine's home turf

Bedside Cheat Sheet